studi
popul
unselect
prospect
accru
cohort
pediatr
adult
patient
receiv
allogen
autolog
hct
myeloabl
condit
weekli
plasma
sampl
patient
collect
day
stem
cell
infus
day
transplant
death
whichev
occur
earlier
sampl
frozen
evalu
batch
evid
aav
viremia
patient
gave
inform
consent
studi
approv
fred
hutchinson
cancer
research
center
institut
review
board
quantit
pcr
assay
develop
detect
aav
subtyp
modifi
primer
set
accord
previous
publish
sequenc
design
specif
taqman
probe
set
primerprob
set
test
set
deriv
detect
aav
strain
except
similar
improv
effici
typespecif
probe
could
detect
set
therefor
final
pcr
reaction
contain
primer
probe
deriv
dna
extract
plasma
use
dna
blood
kit
qiagen
tissu
biopsi
specimen
use
tissu
kit
biorobot
workstat
qiagen
dna
elut
ae
buffer
total
dna
use
pcr
reaction
pcr
reaction
consist
quantitect
multiplex
pcr
master
mix
qiagen
nmoll
primer
aactggaccaatgagaactttcc
nmoll
modifi
primer
aaaaagtctttgacttcctgctt
aaaaagtccttgacttcctgttt
nmoll
probe
probe
famttgcaagaccggatgttcaaattttamra
probe
famctgcaggaccggatgtttgaattttamra
exo
intern
control
spike
pcr
master
mix
monitor
falseneg
result
describ
elsewher
fast
realtim
pcr
system
appli
biosystem
use
test
pcr
reaction
pcr
cycl
condit
minut
activ
polymeras
follow
cycl
minut
specif
pcr
reaction
test
strain
adenovirus
human
genom
cytomegaloviru
cmv
epstein
barr
viru
varicella
zoster
viru
human
herpesviru
hhv
herp
simplex
viru
jc
viru
bk
viru
parvoviru
cross
amplif
detect
assay
detect
strain
aav
obtain
american
type
cultur
collect
sensit
detect
copi
aav
consist
specif
confirm
detect
aav
dna
extract
plasma
sampl
peripher
blood
mononuclear
cell
sampl
saliva
sampl
collect
healthi
volunt
bronchoalveolar
lavag
bal
tissu
specimen
obtain
autopsi
context
clinic
care
process
real
time
pathogen
bacteri
viral
fungal
organ
describ
elsewher
residu
sampl
store
bal
tissu
specimen
obtain
autopsi
patient
aav
detect
plasma
test
aav
quantit
pcr
bal
lung
tissu
sampl
addit
test
pcr
use
publish
protocol
fungal
pathogen
respiratori
virus
includ
respiratori
syncyti
viru
adenovirus
influenza
virus
b
parainfluenza
viru
type
human
metapneumoviru
rhinovirus
acut
respiratori
syndrom
coronaviru
subtyp
clinic
laboratori
radiograph
find
correl
aav
viremia
event
patient
studi
evalu
previous
cmv
plasma
viremia
subset
evalu
previous
bk
viru
adenoviru
viremia
data
explor
evid
coinfect
patient
aav
viremia
hct
recipi
receiv
hlamatch
relat
transplant
receiv
mismatch
relat
transplant
receiv
unrel
transplant
receiv
autolog
transplant
thirtyseven
patient
die
within
day
transplant
mean
age
patient
undergo
hct
year
patient
younger
year
men
underli
diseas
describ
elsewher
aav
detect
plasma
sampl
hct
recipi
patient
virolog
characterist
outlin
tabl
clinic
correl
aav
viremia
describ
tabl
briefli
aav
detect
mean
day
rang
day
transplant
averag
viral
load
copiesml
durat
viral
detect
brief
rang
week
median
durat
week
two
patient
aav
viremia
patient
admit
hospit
lung
infiltr
develop
pulmonari
failur
die
within
week
week
respect
aav
detect
aav
detect
bal
tissu
specimen
lung
gut
liver
kidney
spleen
lymph
node
taken
autopsi
either
patient
postmortem
examin
show
cytolog
chang
suggest
viral
infect
lung
patient
show
evid
diffus
alveolar
damag
consist
find
bud
yeast
form
bal
specimen
candida
glabrata
detect
pcr
assay
bal
fluid
patient
fungal
viral
pathogen
detect
bal
lung
tissu
specimen
patient
note
patient
pcr
evid
bk
viru
adenoviru
viremia
concomit
aav
detect
likewis
lowlevel
viremia
occur
close
proxim
aav
detect
patient
cmv
detect
patient
clinic
find
unsubstanti
patient
report
nausea
diarrhea
found
hyperbilirubinemia
grade
graft
versu
host
diseas
within
one
week
aav
viremia
event
die
unrel
caus
day
patient
die
day
relaps
diseas
neither
patient
abnorm
pulmonari
complic
associ
aav
detect
aav
detect
blood
hct
recipi
incid
low
viremia
transient
aav
appear
play
pathogen
role
organspecif
ill
even
highli
immunocompromis
popul
studi
import
help
defin
virolog
characterist
clinic
epidemiolog
aav
viru
increasingli
use
deliveri
mechan
gene
therapi
newergener
vaccin
aav
attract
candid
use
viral
vector
stem
abil
infect
divers
human
cell
line
specif
integr
host
genom
presum
nonpathogen
howev
littl
work
done
evalu
clinic
epidemiolog
associ
wildtyp
aav
viru
previous
studi
highli
immunocompromis
patient
although
studi
wildtyp
aav
histor
focus
serolog
identif
prior
latent
infect
hospit
patient
use
molecular
diagnost
techniqu
demonstr
instanc
acut
aav
viremia
cohort
immunocompromis
hct
recipi
although
patient
die
pulmonari
complic
proxim
viremia
week
aav
detect
bal
lung
tissu
specimen
tissu
specimen
either
patient
autopsi
specimen
lack
histopatholog
evid
viral
infect
howev
number
case
small
unknown
whether
aav
would
caus
histolog
chang
human
tissu
whether
histopatholog
chang
occur
would
helper
viru
overal
death
plausibl
explain
aspergillu
pneumonia
case
idiopath
pneumonia
syndrom
leukem
relaps
case
given
histori
earli
aspergillu
infect
patient
potenti
residu
diseas
patient
may
also
die
fungal
pneumonia
although
find
pcr
evid
fungi
lung
tissu
specimen
interest
addit
aav
viremia
patient
evid
concomit
viremia
bk
viru
adenoviru
although
viral
load
low
patient
facilit
releas
vitro
aav
host
genom
protein
helper
herpesvirus
adenovirus
well
describ
yet
report
vivo
codetect
symptomat
human
small
epidem
adenoviru
conjunct
pharyng
aav
coisol
adenoviru
secret
patient
studi
first
document
codetect
known
helper
virus
aav
immunocompromis
patient
half
patient
cohort
viremia
dna
virus
strength
studi
use
consecut
unselect
cohort
weekli
prospect
collect
plasma
sampl
quantit
assess
aav
bal
tissu
sampl
broadrang
molecular
test
rule
potenti
caus
diseas
limit
includ
lack
tissu
specimen
eg
urin
stool
absenc
newli
character
human
aav
serotyp
pcr
analys
although
assay
cover
common
serotyp
use
aav
vector
unknown
whether
frequenc
clinic
manifest
uncov
subtyp
would
differ
subtyp
summari
lowlevel
transient
aav
viremia
detect
hct
recipi
incid
low
aav
appear
caus
organspecif
ill
even
highli
immunocompromis
popul
